Total Payments
$8,986
2024 Payments
$451.76
Companies
50
Transactions
622
Medicare Patients
66,903
Medicare Billing
$2.2M
Payment Breakdown by Category
Food & Beverage$8,941 (99.5%)
Education$37.07 (0.4%)
Travel$7.59 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $8,941 | 617 | 99.5% |
| Education | $37.07 | 4 | 0.4% |
| Travel and Lodging | $7.59 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $1,708 | 116 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $827.29 | 52 | $0 (2024) |
| Amgen Inc. | $530.55 | 31 | $0 (2024) |
| ABBVIE INC. | $493.45 | 43 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $454.39 | 20 | $0 (2024) |
| PFIZER INC. | $445.01 | 42 | $0 (2022) |
| Janssen Pharmaceuticals, Inc | $417.92 | 27 | $0 (2021) |
| Amarin Pharma Inc. | $400.24 | 20 | $0 (2022) |
| Astellas Pharma US Inc | $353.11 | 23 | $0 (2021) |
| Lilly USA, LLC | $304.77 | 20 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $451.76 | 28 | Novo Nordisk Inc ($179.09) |
| 2023 | $506.38 | 25 | Novo Nordisk Inc ($167.82) |
| 2022 | $755.63 | 41 | Novo Nordisk Inc ($244.68) |
| 2021 | $1,538 | 102 | Novo Nordisk Inc ($297.59) |
| 2020 | $710.69 | 56 | Novo Nordisk Inc ($122.71) |
| 2019 | $1,199 | 70 | Amgen Inc. ($202.81) |
| 2018 | $1,440 | 100 | Novo Nordisk Inc ($333.64) |
| 2017 | $2,384 | 200 | Boehringer Ingelheim Pharmaceuticals, Inc. ($254.43) |
All Payment Transactions
622 individual payment records from CMS Open Payments — Page 1 of 25
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Abbott Laboratories | — | Food and Beverage | In-kind items and services | $18.56 | General |
| Category: Diabetes Care | ||||||
| 12/17/2024 | Seqirus USA Inc | Flucelvax (Biological), Fluad | Food and Beverage | In-kind items and services | $20.03 | General |
| Category: Vaccines | ||||||
| 12/16/2024 | Boston Scientific Corporation | — | Food and Beverage | In-kind items and services | $18.99 | General |
| Category: General - Pain Management_NMD | ||||||
| 12/10/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $25.89 | General |
| Category: Diabetes | ||||||
| 11/18/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $25.89 | General |
| Category: Diabetes | ||||||
| 09/30/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $15.93 | General |
| Category: PSYCHIATRY | ||||||
| 09/05/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $9.32 | General |
| Category: Diabetes | ||||||
| 08/22/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $10.03 | General |
| Category: Diabetes | ||||||
| 08/21/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $19.67 | General |
| Category: Diabetes | ||||||
| 07/25/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $7.31 | General |
| Category: Diabetes | ||||||
| 07/09/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $23.55 | General |
| Category: NEUROSCIENCE | ||||||
| 06/13/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $19.67 | General |
| Category: Diabetes | ||||||
| 05/31/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $19.16 | General |
| Category: Respiratory | ||||||
| 05/30/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $11.78 | General |
| Category: Obesity | ||||||
| 05/16/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $16.32 | General |
| Category: Respiratory | ||||||
| 05/13/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $19.96 | General |
| Category: RESPIRATORY | ||||||
| 05/06/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $16.95 | General |
| Category: GASTROENTEROLOGY | ||||||
| 04/05/2024 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Food and Beverage | In-kind items and services | $19.89 | General |
| Category: VACCINES | ||||||
| 04/05/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $5.98 | General |
| 03/25/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $15.87 | General |
| 03/14/2024 | Xeris Pharmaceuticals, Inc. | KEVEYIS (Drug) | Food and Beverage | In-kind items and services | $14.65 | General |
| Category: Carbonic anhydrase inhibitor | ||||||
| 03/08/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $10.18 | General |
| Category: Obesity | ||||||
| 03/05/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $16.58 | General |
| Category: GASTROENTEROLOGY | ||||||
| 02/22/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $6.67 | General |
| Category: Diabetes | ||||||
| 02/21/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $19.61 | General |
| Category: Inflammation | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 72 | 17,712 | 26,992 | $1.7M | $610,459 |
| 2022 | 78 | 17,262 | 25,713 | $1.7M | $581,928 |
| 2021 | 75 | 17,015 | 25,579 | $1.6M | $582,752 |
| 2020 | 77 | 14,914 | 20,101 | $1.3M | $400,400 |
Total Patients
66,903
Total Services
98,385
Medicare Billing
$2.2M
Procedure Codes
302
All Medicare Procedures & Services
302 procedure records from CMS Medicare Utilization — Page 1 of 13
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 821 | 821 | $176,515 | $97,986 | 55.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 748 | 755 | $207,625 | $81,169 | 39.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 767 | 1,255 | $175,700 | $68,274 | 38.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 533 | 783 | $160,515 | $63,818 | 39.8% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 945 | 1,086 | $61,902 | $22,861 | 36.9% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 1,006 | 1,269 | $82,485 | $20,888 | 25.3% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 1,010 | 1,528 | $82,512 | $19,960 | 24.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 1,091 | 2,330 | $46,600 | $19,526 | 41.9% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 1,062 | 1,808 | $65,088 | $18,646 | 28.6% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 58 | 58 | $31,900 | $16,052 | 50.3% |
| 82306 | Vitamin d-3 level | Office | 2023 | 465 | 490 | $39,690 | $14,161 | 35.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 1,061 | 1,784 | $58,872 | $13,538 | 23.0% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 746 | 746 | $22,380 | $12,553 | 56.1% |
| 84403 | Testosterone (hormone) level, total | Office | 2023 | 443 | 461 | $47,022 | $11,659 | 24.8% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2023 | 72 | 72 | $23,400 | $11,001 | 47.0% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2023 | 61 | 61 | $19,215 | $9,338 | 48.6% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 872 | 923 | $57,226 | $8,480 | 14.8% |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | Office | 2023 | 422 | 422 | $27,430 | $7,991 | 29.1% |
| 82550 | Creatine kinase (cardiac enzyme) level, total | Office | 2023 | 693 | 1,143 | $32,004 | $7,264 | 22.7% |
| 87502 | Detection test by nucleic acid for multiple types influenza virus | Office | 2023 | 66 | 70 | $13,440 | $6,572 | 48.9% |
| 86235 | Measurement of antibody for assessment of autoimmune disorder, any method | Office | 2023 | 37 | 370 | $16,650 | $6,501 | 39.0% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2023 | 188 | 188 | $56,400 | $6,452 | 11.4% |
| 82607 | Cyanocobalamin (vitamin b-12) level | Office | 2023 | 294 | 357 | $21,420 | $5,237 | 24.4% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2023 | 84 | 93 | $9,486 | $4,676 | 49.3% |
| 82746 | Folic acid level, serum | Office | 2023 | 267 | 309 | $17,922 | $4,414 | 24.6% |
About Dr. John Buttross, MD
Dr. John Buttross, MD is a Internal Medicine healthcare provider based in Memphis, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1053370213.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Buttross, MD has received a total of $8,986 in payments from pharmaceutical and medical device companies, with $451.76 received in 2024. These payments were reported across 622 transactions from 50 companies. The most common payment nature is "Food and Beverage" ($8,941).
As a Medicare-enrolled provider, Buttross has provided services to 66,903 Medicare beneficiaries, totaling 98,385 services with total Medicare billing of $2.2M. Data is available for 4 years (2020–2023), covering 302 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Memphis, TN
- Active Since 03/17/2006
- Last Updated 08/01/2011
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1053370213
Products in Payments
- Ozempic (Drug) $635.64
- FARXIGA (Drug) $545.86
- Vascepa (Drug) $400.24
- Aimovig (Biological) $325.15
- Victoza (Drug) $286.36
- PREVNAR - 13 (Biological) $245.82
- VRAYLAR (Drug) $240.60
- JARDIANCE (Drug) $239.11
- XARELTO (Drug) $221.47
- Myrbetriq (Drug) $197.79
- INVOKANA (Drug) $190.43
- JANUVIA (Drug) $185.78
- Trintellix (Drug) $182.99
- Rybelsus (Drug) $170.83
- UBRELVY (Drug) $169.26
- FREESTYLE LIBRE 2 (Device) $163.23
- MYRBETRIQ (Drug) $155.32
- TRIGEN Femoral (FAN/TAN/Meta Nail) (Device) $139.40
- Dayvigo (Drug) $137.22
- STIOLTO (Drug) $134.40
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Memphis
Patricia Adams-Graves, Md, MD
Internal Medicine — Payments: $275,584
Internal Medicine $275,584
Phillip Northcross, M.c, M.C
Internal Medicine — Payments: $88,005
Internal Medicine $88,005
Dr. William Cushman, Md, MD
Internal Medicine — Payments: $74,181
Internal Medicine $74,181
Dr. Rajesh Kabra, Md, MD
Internal Medicine — Payments: $50,656
Internal Medicine $50,656
Dr. Pedro Velasquez, Md, MD
Internal Medicine — Payments: $44,386
Internal Medicine $44,386
Saurin Chokshi
Internal Medicine — Payments: $43,695
Internal Medicine $43,695